Introduction
Experimental support fbr the hypothesis that adrenocorticotropin (ACTH) secretion was controlled by hypothalamic factors, was obtained in 1955. 2'3 In 1981, a 41 amino acid C terminal amidated peptide from ovine hypothalami stimulating pituitary ACTH release in vitro was identified and characterized. 4 The biologically active form of this peptide, designated corticotropin releasing hormone (CRH), and also frequently referred to as corticotropin releasing factor (CRF), was synthesized and found to have potent ACTH-releasing actions in vivo. 5 CRH is the only permissive factor for the anterior pituitary release of ACTH known in man 5'6 and acts in synergy with arginine vasopressin (AVP) and, perhaps, other factors, to regulate pituitary ACTH secretion, and, therefore ultimately the activity of the pituitaryadrenal axis. [7] [8] [9] Since its discovery, it has become evident that CRH has roles which are much wider than initially thought. Thus, coordination of the behavioral and physical components of the stress response and regulation of the immune/inflammatory reaction were unravelled as major overall roles of this neuropeptide. ' In addition, this peptide was implicated in the pathophysiology of a large range of diseases associated with dysregulation of 12 the stress system and autoimmunity. Because of the central roles of CRH in homeostasis and pathogenesis of disease, knowledge of its gene (C) 1995 Rapid Communications of Oxford Ltd and its regulation would be essential for further progress. This brief review will outline the most critical aspects of CRH biology, will summarize the structure, function and regulation of the human (h) CRH gene by steroid hormones, and will introduce a tentative model to account for its tissue-specific antithetical hormonal responses. The implications of the regulatory potential of the hCRH gene for the sexual dimorphism of the stress response and immune/inflammatory reaction will also be discussed.
Overview of CRH biology
CRH is synthesized as part of a prohormone, it is processed enzymatically, and in addition undergoes enzymatic modification to the amidated form. Mammalian CRH has homologies with non-mammalian vertebrate peptides x CRH and sauvagine 4 in amphibia (from frog brain/spleen and skin, respectively), urotensin-I in teleost fish 5 and the two diuretic peptides Mas-DPI and Mas-DPII from the tobacco hornworm Manduca sexta. 16 '17 The vertebrate homologues have been tested and found to possess potent mammalian and fish pituitary ACTHreleasing activity. In addition, they decrease peripheral vascular resistance and cause hypotension when injected into mammals. 15'18'19 The amino terminus of CRH is not essential for binding to the receptor, whereas absence of the carboxy terminal amide abolishes CRH binding to its receptor. Oxidation of a methionine residue coordinate the overall stress response. 4 High abolishes the biological activity of CRH, and this doses of CRH cause behaviors characteristic of may be a mechanism for neutralization of the anxiety, suggesting that the behavioral effects of peptide in vivo. 5 71'72 This is in well as in the -400 bp 5' flanking region of contrast to other bZIP members (e.g., c-jun 72 POMC,_ rat growth hormone and other hormone and C/EBPV3), which are encoded by intronless genes. 64 The sequence of a 3.7 kb stretch into genes. 74 The latter proteins can heterodimerize the 5' flanking region of the hCRH gene was with some members of the CREB/ATF family of also determined (Gene Bank accession no. proteins. 75 81 82 shown in Fig. 2   65 and rat CRH promoter-driven CAT constructs. TATA boxes have also been implicated in tran-glucocorticoids.
The antithetical glucoscriptional regulation by the p53 growth sup-corticoid effects on a hCRH promoter-drive CAT pressor gene. More specifically, p53 appears to construct may be explained by the stimulation of control cellular activity by suppressing the tranthe half GREs by high levels of ligand-bound GR, scription of genes with a TATA box in their pro-which presumably override the blockade of tranmoter region through direct interaction. 25 The scription exerted by lower levels of the activated region-1.7 to-3.3 kb flanking the hCRH gene GR through interaction with cjun-cfos, as dishas a total of eight additional TATA boxes, which cussed above. Is this mechanism physiologically might also interact Tissue-specific and stress-related instance, tissues with high hsp90 content appear expression of the hCRH gene to be quite sensitive to glucocoricoids in contrast with tissues with a low hsp90 content, m '28 As discussed above, the CRH gene is widely and as hsp90 content increases one would expressed throughout the body, suggesting that expect a parallel increase of the effective conits product may have autocrine or paracrine centration of tissue GR. 97 introduces a hypothetical general mechanism to account for the differential sensitivity and direction of effects of various tissues to glucocorticoids. This mechanism involves genes that are regulated by both the growth-promoting AP1 factors and by the differentiation-promoting, antigrowth glucocorticoid hormones. Since the hCRH gene contains both types of enhancers in its promoter region, it may potentially respond as outlined in Fig. 3 . The mechanism proposed in Fig. 3 142 143 in women than in men. 3 Also, the same find-cortisol making them strictly analogous to ings may explain why puberty/adolescence, the the Lewis rat model of autoimmune/inflammatory 139 140 postpartum and the perimenopausal period, disease.
during all of which marked changes in estrogen The above studies suggest that homeostatic production take place, are characterized by regulation involves complex mutual interactions increased incidence of emotional disorders, between the reproductive axis, HPA axis and In addition to explaining the slightly increased, the immune system, in which t2 and CRH may basal and stress stimulated HPA axis function in play central roles (Fig. 4) . Certainly 
